Amplification and rearrangements of the epidermal growth factor receptor (EGFR) gene are frequently found in glioblastoma multiforme (GBM). The most common variant is EGFR variant III (EGFRvIII). Research suggests that EGFRvIII could be a marker for a cancer stem cell or tumor-initiating population. If amplification and rearrangement are early events in tumorigenesis, this implies that they should be preserved throughout the tumor. However, in primary GBM, EGFRvIII expression is focal and sporadic. Unexpectedly, we found EGFR amplification and rearrangement throughout the tumor, including regions with no EGFRvIII expression, suggesting that mechanisms exist to modulate EGFRvIII expression even in the presence of high gene amplification. To study this phenomenon, we characterized three GBM cell lines with endogenous EGFRvIII. EGFRvIII expression was heterogeneous, with both positive and negative populations maintaining the genetic alterations, akin to primary tumors. Furthermore, EGFRvIII defined a hierarchy where EGFRvIII-positive cells gave rise to additional positive and negative cells. Only cells that had recently lost EGFRvIII expression could re-express EGFRvIII, providing an important buffer for maintaining EGFRvIII-positive cell numbers. Epigenetic mechanisms had a role in maintaining heterogeneous EGFRvIII expression. Demethylation induced a 20-60% increase in the percentage of EGFRvIII-positive cells, indicating that some cells could re-express EGFRvIII. Surprisingly, inhibition of histone deacetylation resulted in a 50-80% reduction in EGFRvIII expression. Collectively, this data demonstrates that EGFR amplification and rearrangement are early events in tumorigenesis and EGFRvIII follows a model of hierarchical expression. Furthermore, EGFRvIII expression is restricted by epigenetic mechanisms, suggesting that drugs that modulate the epigenome might be used successfully in glioblastoma tumors.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and deadly primary brain tumor, carrying a dismal prognosis and accounting for over 50% of diagnosed brain tumors every year. 1 Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene are observed frequently in GBM. 2 The most common deletion mutant is EGFR variant III (EGFRvIII), which has been identified in a high percentage of GBM cases. [3] [4] [5] Other tumors have also been shown to express this variant, including lung, breast, ovarian and prostate cancer, but EGFRvIII is rarely expressed in normal tissue. [6] [7] [8] [9] [10] EGFRvIII is most often the product of a genomic rearrangement and amplification of the EGFR locus, resulting in an 801-bp in-frame deletion of exons 2-7. This gives rise to a truncated receptor that maintains its signal peptide, transmembrane and intracellular kinase and autophosphorylation domains, but lacks a significant portion of the extracellular ligand-binding domain, rendering EGFRvIII ligand-independent and constitutively active. A novel glycine is produced at the splice-junction, representing a potential tumorspecific antigen with significant therapeutic potential. 11, 12 Putative GBM cancer stem cells (CSC) have been identified via the cell surface markers CD133 and CD15, but using these molecules as targets is complicated by their expression in normal non-cancerous tissue. 13, 14 There is evidence that EGFRvIII can be preferentially associated with a CSC population. The CSC population in glioblastoma has been shown to be more chemoand radioresistant. 15 EGFRvIII is known to confer chemo-and radiationresistance, suggesting that EGFRvIII marks a critical population of cells required for tumorigenesis or tumor progression. 16, 17 Additionally, glioma-like lesions have been shown to occur more frequently when an activated EGFR mutant similar to EGFRvIII was expressed from a nestin-specific promoter and EGFRvIII expression in post-natal neural stem cells could block neuronal differentiation. 18, 19 More directly, our lab has provided preliminary evidence that EGFRvIII does indeed mark a tumor-initiating or CSC population in GBM, where EGFRvIII shows a preferential association with CD133-expressing cells and the EGFRvIII þ CD133 þ population has the highest incidence of selfrenewal and tumorigenicity in mice (Wong et al. 20 and Emlet et al., unpublished data).
As EGFRvIII results from genomic amplification and rearrangement, if EGFRvIII marks a CSC population this would suggest that EGFR amplification and rearrangement are early events in tumorigenesis. In support of this notion, southern blots and genomic PCR reveal that the rearrangement is clonal. 21, 22 Thus, the underlying genomic alterations should be conserved throughout the tumor. Interestingly, rather than diffuse staining across the tumor, the typical pattern of expression for EGFRvIII is either focal areas or sporadic-positive cells. 23, 24 These patterns are in line with the more restricted expression of CSC, but the status of the EGFR genomic alteration in both EGFRvIII-positive and -negative regions of a tumor remains to be determined. Here, we have investigated the underlying EGFR amplification and rearrangement patterns present in EGFRvIII-expressing GBM and established three cell line models for the study of endogenous EGFRvIII in GBM.
RESULTS
EGFR amplification and rearrangement are present in both EGFRvIII-positive and -negative regions of primary GBM Based on evidence suggesting that the EGFRvIII rearrangement is clonal and EGFRvIII marks a CSC population, we hypothesized that EGFRvIII amplification and rearrangement were early events in tumorigenesis, and thus should be preserved throughout the tumor. To test this hypothesis, we investigated the relationship between EGFRvIII expression and EGFR amplification and rearrangement in primary GBM. We first analyzed several primary GBM by immunohistochemistry (IHC) using an EGFRvIII-specific antibody that does not recognize wild-type EGFR (wtEGFR). We found heterogeneous staining patterns in accordance with the literature (Figure 1a) . Next, we manually dissected EGFRvIII-positive and -negative regions from GBM sections and performed quantitative PCR (qPCR) to assay for the presence of EGFR amplification and rearrangement utilizing primer sets internal (exon 2) and external (intron 15) to the deleted region. 25 The ratio of these two primers relative to b-actin indicates whether wtEGFR or EGFRvIII amplification is present. If rearrangement has occurred, the relative amount of DNA amplified from within intron 15 should be greater than that from within exon 2. Interestingly, we observed two major patterns (Figure 1b) . One pattern demonstrated high-level amplification and rearrangement in both EGFRvIII-positive and -negative regions (Figure 1b, GBM1-4) . The other showed high-level amplification and rearrangement in EGFRvIII-positive cells, and lower-level, but detectable, amplification and rearrangement in EGFRvIII-negative cells (Figure 1b , GBM-5 and GBM-6). From these analyses, we can conclude that at least a subset of GBM are characterized by widespread amplification and rearrangement of the EGFR locus with expression of EGFRvIII limited to sub-regions or sporadic cells within these tumors, confirming our hypothesis.
Cell lines display heterogeneous EGFRvIII expression
Under standard tissue culture conditions, nearly all primary glioblastoma tumors lose EGFR gene amplification. 26 As a result, research into the role of EGFRvIII has been hampered by lack of in vitro cell line models. Furthermore, many cells lines lack the heterogeneity that is the hallmark of glioblastoma. Recently two cell lines, DKMG and CAS-1, have been discovered to maintain EGFR amplification and rearrangement and expression of EGFRvIII (C Giacomini et al., unpublished data). Additionally, we have identified another cell line with EGFR amplification and EGFRvIII expression, bs153. 27 To test whether these cell lines recapitulate the heterogeneity of EGFRvIII expression observed in primary GBM, we analyzed each cell line by flow cytometry. We found robust endogenous EGFRvIII expression maintained in all three cell lines and this expression was heterogeneous, with between 9 and 50% of the cells being EGFRvIII positive (Figure 2a) . Sorting of DKMG EGFRvIII-positive and -negative cells by flow cytometry and subsequent western blotting confirmed the molecular weight of EGFRvIII and its presence in only the EGFRvIII-positive sorted population (Figure 2b ).
Additionally, our previous studies have indicated that cells expressing EGFRvIII have increased CSC-associated properties compared with non-expressing cells (Emlet et al., unpublished data). We performed limiting dilution sphere formation analysis utilizing EGFRvIII-positive and -negative sorted populations from the DKMG cell line to determine if the two populations had different functional properties. The EGFRvIII-positive population formed a higher number of spheres and had a higher sphere-initiating frequency than the EGFRvIII-negative population (Figures 2c, d) , again recapitulating results obtained using primary tumor cells. Interestingly, we noted striking morphological differences between EGFRvIII-positive and -negative populations in the bs153 cell line. EGFRvIII-positive cells were more elongated and spindle-like, whereas EGFRvIII-negative cells displayed more epithelial-like morphology, confirming that there could also be a morphologic heterogeneity associated with EGFRvIII expression (Figure 2e ). DKMG cells maintain rearrangement and amplification of the EGFR locus in both EGFRvIII-positive and -negative populations To determine whether these cell lines recapitulate the genomic patterns observed in primary GBM, we characterized amplification and rearrangement of the EGFR locus in the DKMG cell line by assessing the EGFR gene status in both the EGFRvIII-positive and -negative populations. First, we performed long-range PCR utilizing a method adapted from Frederick et al. 28 This method employs a single antisense primer located in exon 8, and 1 of the 2 sense primer mixtures containing oligonucleotides spaced at B10 kb intervals throughout intron 1, the size of which is greater than 120 kb. If no rearrangement has occurred, the distance between the sense and antisense primers is too large to amplify, thus a positive band with either of the two sense primer sets indicates that the EGFRvIII rearrangement has occurred. Longrange PCR revealed the presence of the rearrangement in both the EGFRvIII-positive and -negative populations, but a much weaker band was observed in the negative population (Figure 3a ). An identical junction corresponding to rearranged EGFRvIII was identified in each population by sequencing (Figure 3b ). qPCR confirmed this result, revealing high-and low-level amplification and rearrangement in EGFRvIII-positive cells and -negative cells, respectively ( Figure 3c ). As this analysis was performed on bulk sorted cells, the low-level amplification and rearrangement could have arisen from two scenarios. Either the majority of cells within the population have low-level amplification and rearrangement or there is a minority of cells with high-level amplification. To distinguish between these two possibilities, we looked at amplification on a cell-by-cell basis utilizing FISH. Amplification was observed in both populations by FISH analysis (Figure 3d ). Quantification of probe signals revealed that both EGFRvIIInegative and -positive populations had a wide range of amplification, but EGFRvIII-negative cells did maintain at least low-level amplification (median 10 copies per cell) in the majority of cells examined, compared with 22 copies per cell in the EGFRvIII-positive cells (Figures 3e, f) .
EGFRvIII expression defines a cellular hierarchy To understand how this heterogeneous population of EGFRvIIIpositive and -negative cells are formed, we sorted both populations and re-analyzed the cultured cells for EGFRvIII expression at various timepoints over a 2-month period. We observed that EGFRvIII-positive cells gradually gave rise to both positive and negative cells, but negative cells did not form positive cells (Figure 4a ). Given that the genomic analyses revealed that these EGFRvIII-negative cells maintain lower level EGFR amplification and rearrangement than the EGFRvIII-positive cells, this implies two possible scenarios: (1) amplification is lost first and then expression is downregulated or (2) expression is downregulated first and amplification is subsequently lost. To distinguish between these two possibilities, we generated a population of cells that we will refer to as 'EGFRvIII-negative shortterm cells.' These cells were derived from EGFRvIII-positive cells after B2 weeks in culture. This is in contrast to the EGFRvIIInegative population we used in the initial analyses ( Figures 2-4 , here called EGFRvIII-negative long-term cells), which had lacked EGFRvIII expression in culture for several months. We assessed the amplification and rearrangement status in these short-term cultured cells. Cells were sorted and subjected to qPCR. Interestingly, cells within this EGFRvIII-negative short-term population contained similar amounts of EGFR amplification and rearrangement as EGFRvIII-positive cells, differing from the EGFRvIII-negative long-term cells that have lower-level amplification ( Figure 4b ). This suggests that cells with high-level amplification and rearrangement first lose expression of the receptor, and second, cells slowly lose the amplicons themselves.
As these EGFRvIII-negative short-term cells maintain similar levels of amplification as EGFRvIII-positive cells, we tested whether they have the ability to spontaneously re-express EGFRvIII. Sorted Primary human GBM tumor FFPE sections from (a) were utilized for subsequent DNA isolation. For GBM1-6, EGFRvIII-positive and -negative regions were manually dissected and separated. qPCR was performed with two primer sets, one within the EGFRvIII-deleted region (exon 2), and the other external to the EGFRvIII-deleted region (intron 15). Relative copy number was determined using the comparative C t method. U87-MG DNA served as the normal control, as it lacks amplification or rearrangement of EGFR and contains a normal copy number of chromosome 7. A GBM xenograft with known EGFRvIII rearrangement and amplification served as the positive control for EGFRvIII amplification (vIII þ Cont), and A431 DNA was a positive control for wtEGFR amplification.
EGFRvIII-positive and EGFRvIII-negative short-term populations were allowed to propagate in culture for 4 weeks and re-analyzed for EGFRvIII expression. Unlike the EGFRvIII-negative long-term cells that could not reform additional EGFRvIII-positive cells, 10% of the short-term cultured cells did regain expression of EGFRvIII (Figure 4c ). If EGFRvIII does mark a CSC population, this data suggests that the ability of differentiated progenitors that lack EGFRvIII expression to revert to a CSC phenotype is confined to a short-time frame beyond which the cells can no longer dedifferentiate. Gates were determined using the isotype controls and denote the EGFRvIII þ / À populations. (b) DKMG EGFRvIII þ / À populations were sorted by FACS, allowed to expand in culture and whole-cell lysates were used in western blot analysis with an anti-EGFRvIII antibody. As a positive control, U87-MG cells were transfected with EGFRvIII (U87-vIII). A431 cells, with amplified wtEGFR, and parental U87-MG cells were used as negative controls. (c) Sorted EGFRvIII þ / À cells were plated in a series of limiting cell doses down to a single cell per well. The average number of neurospheres per well was calculated across three replicates. Error bars show standard deviation for each cell dose, *indicates statistically significant differences between EGFRvIII þ / À cells (Po0.05). (d) Sphere-initiating frequency was calculated utilizing limiting dilution linear regression analysis. The frequency of self-renewing cells was greater in EGFRvIII þ (1/39) than EGFRvIII À (1/279) populations (Po0.01). (e) bs153 EGFRvIII þ / À populations were sorted by FACS, allowed to expand in culture, and images were taken to capture morphological differences.
EGFRvIII expression can be modulated by altering methylation and acetylation patterns From the above analyses it appears that EGFRvIII expression is lost despite the fact that EGFR amplification and rearrangement remain. Numerous mechanisms exist by which gene expression patterns are modulated. Methylation is a well-known way in which cells can modulate gene expression by preventing DNA transcription. Several known compounds act as potent demethylating agents, a commonly utilized reagent is 5-aza-2'-deoxycytidine (AZA). We utilized AZA to determine if demethylation could alter EGFRvIII expression in sorted EGFRvIII-negative long-term cells or an unsorted population containing EGFRvIII-positive and shortterm negative cells. After exposure to AZA or vehicle control (DMSO) for 48 h, the DKMG and bs153 cell lines were analyzed by flow cytometry to determine the percentage of EGFRvIII-positive cells. AZA was not able to induce EGFRvIII expression in long-term cultured EGFRvIII-negative cells from either cell line (Figures 5a, b) . However, we observed a 20-30% increase in EGFRvIII-positive cells from the unsorted population in the DKMG and bs153 cell lines (Figures 5a, b) . Although we did observe an increase in EGFRvIIIpositive cells, not all of the cells re-expressed EGFRvIII. It is possible that other mechanisms regulate EGFRvIII gene expression.
Histone acetylation is another prominent method employed by cells to modulate their gene expression. Histone deacetylation inhibitors (HDACi) are thought to mediate anti-tumor effects by modulating chromatin structure. Trichostatin A (TSA) is a widely used potent histone deacetylase inhibitor. When DKMG, bs153 and CAS-1 cells were treated with TSA for 48 h, we noted the Figure 3 . DKMG cells have EGFRvIII amplification and rearrangement that is maintained at a low level in non-EGFRvIII-expressing cells. (a) DNA was isolated from DKMG EGFRvIII þ / À sorted cells and long-range PCR was performed to identify the EGFRvIII genomic rearrangement. Xenograft sample 270x was a positive control for EGFRvIII rearrangement and amplification, and U87 DNA was a negative control. A, primer mixture A, B, primer mixture B, þ , EGFR-positive control primer set (forward primer in exon 13, reverse primer in exon 16). (b) The intron1-intron7 junction corresponding to rearranged EGFRvIII was identified in both EGFRvIII þ / À populations by sequencing. (c) qPCR was performed on EGFRvIII þ / À sorted cells. Two primer sets, one within the EGFRvIII-deleted region (exon 2), and the other external to the EGFRvIII-deleted region (intron 15) were utilized and the relative copy number was determined using the comparative C t method. U87 served as the normal control DNA, as it lacks amplification or rearrangement of EGFR and contains a normal copy number of chromosome 7. Xenograft sample 270x was a positive control for EGFRvIII rearrangement and amplification, and A431 DNA was a positive control for wtEGFR amplification. (d) FISH was performed on DKMG EGFRvIII À (upper) and EGFRvIII þ (lower) sorted cells using a probe for the EGFR locus (red) and CEP7 as the chromosome 7 centromeric control probe (green). (e, f ) The number of EGFR amplicons was quantified in 100 cells in each sample. The middle and bottom rows shows EGFRvIII expression in the cells. Gates were determined using the isotype controls and denote the EGFRvIII þ / À populations. (b) qPCR was performed on EGFRvIII short-term negative and positive sorted cells. Two primer sets, one within the EGFRvIII-deleted region (exon 2), and the other external to the EGFRvIII-deleted region (intron 15) were utilized and the relative copy number was determined using the comparative C t method. U87 served as the normal control DNA, as it lacks amplification or rearrangement of EGFR and contains a normal copy number of chromosome 7. Xenograft sample 270x was a positive control for EGFRvIII rearrangement and amplification, and A431 DNA was a positive control for wtEGFR amplification. (c) EGFRvIII-positive (left), EGFRvIII short-term-negative (middle) and EGFRvIII long-term-negative (right) populations were sorted and cultured for an additional 4 weeks and then re-analyzed for EGFRvIII expression by flow cytometry. Top row shows background from the isotype control (mouse IgG1), bottom row shows EGFRvIII expression. Gates were determined using the isotype controls and denote the EGFRvIII þ / À populations.
opposite effect as AZA, with a 50-80% decrease in the percentage of EGFRvIII-positive cells in the three cell lines (Figures 6a, b) . A striking phenotypic change was also noted in each cell line, with cells adopting an elongated, spindle-shaped morphology (Figure 6c) .
To substantiate the epigenetic effects observed in EGFRvIII expressing cell lines, we tested the effects of AZA and TSA on short-term tumor sphere cultures derived from primary GBM samples. Heterogeneous EGFRvIII expression was confirmed by IHC ( Figure 7a ) and each tumor had genomic amplification and rearrangement corresponding to EGFRvIII by FISH and long-range PCR (Figures 7b, c) . The sphere cultures also maintain heterogeneous EGFRvIII expression by RT-PCR and flow cytometry analyses (Figures 7d, f) . Each short-term cultured sphere line was treated with either AZA or TSA. Similar to what we noted above, demethylation led to significant increases in the percentages of EGFRvIII-positive cells, with 28 and 64% increases in EGFRvIII expression observed (Figures 7e, f) . Likewise, treatment with TSA resulted in a 45-60% decrease in EGFRvIII expression in the sphere cultures, again recapitulating what we observed in the cell lines (Figures 7e, f) . Overall, this data indicates that several epigenetic mechanisms might be used to regulate EGFRvIII expression.
DISCUSSION
If EGFRvIII marks a CSC population, then any genetic changes present in the CSC should be present throughout the tumor. Here, we have reconciled this hypothesis with the observation that Figure 5 . Demethylation allows for EGFRvIII re-expression in a subset of EGFRvIII-cells. (a) DKMG and bs153 EGFRvIII-negative long-term and a mixed population containing EGFRvIII-negative short-term and EGFRvIII-positive cells were treated with AZA or vehicle control for 48 h and expression of EGFRvIII (PE labeled, x axis) was analyzed using flow cytometry. Left columns show background from the isotype control (mouse IgG1), middle and right columns shows EGFRvIII expression. Gates were determined using the isotype controls and denote the EGFRvIII þ / À populations. (b) Percentages of EGFRvIII-positive cells were quantified and averaged across three replicates. *Indicates statistically significant differences between cells treated with AZA compared with vehicle control-treated cells (Po0.05).
EGFRvIII shows only focal/sporadic patterns of expression in tumors, demonstrating that EGFR amplification and rearrangement does indeed exist across the tumor in primary GBM. Early studies investigating the structure of EGFR amplicons agree with this hypothesis, demonstrating that amplification results from a singular post-replicative event that circularizes a chromosome fragment overlapping EGFR. This unique amplicon is present throughout the tumor, suggesting it was an early event in tumor initiation. 22 We have found that in some cases parts of the tumor distant from EGFRvIII-positive regions have lower amounts of EGFR amplification. The extrachromosomal circular DNA molecules that harbor EGFR amplification are called double minute chromosomes, and they are known to be unstable, particularly if there is lack of selection pressure. 29 The paucity of GBM cell lines with either EGFR amplification or rearrangement points to a general lack of selection pressure under conventional in vitro culture conditions, except in the few cases where EGFR amplification is maintained. 30 Therefore, a tumor could likewise be comprised of a mixture of cells with high and low amplification resulting from the gradual loss of double minute chromosomes in areas of the tumor where selection pressure is low.
The GBM cell lines used in this study can serve as models for EGFRvIII rearrangement and expression in primary GBM and have provided insights into the regulation of EGFRvIII expression.
Historically, it has been difficult to maintain EGFRvIII expression and underlying genomic amplification and rearrangement in culture. 26, 31, 32 Recently, several groups have reported the ability to maintain expression and amplification utilizing serum-free neurosphere culture techniques. 33, 34 Interestingly, a report by Schulte et al. 35 showed evidence that the initial conditioning of GBM primary tumors will dictate whether they maintain expression and amplification/rearrangement of EGFR, but once the cell line is stably established amplification will be maintained even if the culture conditions are changed. It appears that serumfree (and EGF-free) conditions increase the ability of primary tumor cells to maintain amplification when first placed into culture, potentially explaining the paucity of EGFRvIII-expressing cell lines for so many years, but it is likely that some lines are able to do so in other conditions as well, albeit at a much lower frequency. Although it is relatively rare for conventional cell lines to express EGFRvIII in vitro, we do believe that they accurately reflect EGFRvIII cell biology for the following reasons: (1) these cell lines maintain both heterogeneous expression and the presence of widespread amplification and rearrangement corresponding to EGFRvIII, akin to what we observed in primary tumors, (2) EGFRvIIIpositive cells within the mixed population have increased sphere-initiating frequency compared with EGFRvIII-negative cells, which again recapitulates what we observe in primary tumors and (3) EGFRvIII expression appears to be regulated by similar epigenetic mechanisms in both the cell lines and EGFRvIIIexpressing short-term cultured primary tumor cells.
An interesting finding of this study is that the EGFRvIII-positive population can generate EGFRvIII-negative cells at a small but steady rate. Theoretically, the EGFRvIII-positive pool would eventually disappear. Interestingly, we found that cells that had recently lost EGFRvIII expression, which we termed the EGFRvIIInegative short-term cells, are capable of regaining EGFRvIII expression but that EGFRvIII-negative long-term cells are incapable of reversion. If EGFRvIII expression does mark a CSC population, this suggests that these EGFRvIII-negative short-term cells have an important role in maintaining CSC numbers. It has been shown that apparently differentiated tumor cells can revert to CSCs using appropriate growth factors. 36 Our work extends these observations by indicating that only recently differentiated cells can revert, whereas longer term cells are terminally differentiated.
Our results suggesting a difference between long-term and short-term cultured EGFRvIII-negative cells may imply that there are two processes at work that together result in a heterogeneous population of EGFRvIII-positive and -negative cells. The EGFRvIIInegative short-term cells maintain levels of amplification comparable to EGFRvIII-positive cells and they can re-express EGFRvIII independently of external stimulation over the course of several weeks or more immediately in response to the demethylating agent AZA. This data suggests that there first may be a reversible silencing of EGFRvIII that is not accompanied by loss of amplification or rearrangement. And second, with time there may be the gradual loss of the amplicons themselves, as the cells differentiate and therefore no longer have pressure to maintain the presence of the amplicons.
We also provide surprising evidence that EGFRvIII can be downregulated following treatment with the potent HDACi TSA. HDACi are thought to exert their anti-tumor effects by modulating chromatin structure through histone acetylation. The exact mechanisms are complicated, but regulation of the transcription of key genes controlling cell growth and death by increasing acetylation of promoter-associated histones is thought to be involved. [37] [38] [39] [40] Interestingly, HDACi have been implicated in radiosensitization of GBM and GBM cell differentiation, as treatment of GBM cell lines with TSA induced prominent morphological changes consistent with differentiation, and induction of markers of differentiation. [41] [42] [43] HDACi can also act through changes in acetylation on non-histone targets such as transcription factors. At least 80 clinical trials are underway utilizing HDACi alone or in combination with other treatments, including the HDACi valproic acid for the treatment of GBM. 44 Furthermore, vorinostat, another HDACi, is already FDA approved for the treatment of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease. 45 Given our observed effects of TSA on EGFRvIII expression, patients with EGFRvIIIexpressing tumors may especially benefit from the addition of an HDACi.
MATERIALS AND METHODS Immunohistochemistry
Unstained sections from formalin-fixed paraffin-embedded samples of glioblastoma were acquired from the Neuropathology Laboratory of the Stanford University Medical Center with all patient identifiers removed. Slides were deparaffinized in xylene and then rehydrated with ethanol and then double distilled water (ddH20). Hydrogen peroxide was used to block unspecific sites and the slides were placed in Diva Decloaker (BioCare Medical, Concord, CA, USA) and microwaved for antigen retrieval. After a cooling period, the slides were blocked with background sniper universal serum (BioCare Medical), washed with PBS and then incubated with primary antibody overnight at 4 1C. For EGFRvIII IHC, sections were incubated overnight with a 1:1500 solution of a monoclonal mouse antibody against EGFRvIII (clone G100, formerly commercially available from Zymed lab (Carlsbad, CA, USA), now discontinued), which recognizes EGFRvIII but does not cross-react with wtEGFR. Slides were then washed with PBS and incubated with the HRP anti-mouse secondary antibody (BioCare Medical) and expression was detected by betazoid DAB (BioCare Medical). The slides were then counterstained with hematoxylin.
Quantitative PCR FFPE sections that had been previously used for IHC analysis were utilized for DNA isolation. Real-time qPCR was carried out using a previously published protocol. 25 Briefly, three primer sets were employed, two within the EGFR genome and a third internal control (b-actin). Of the two EGFR primers, one is within the EGFRvIII-deleted region (exon 2) and the other is external to the EGFRvIII-deleted region (intron 15). Each reaction was performed in triplicate in 384-well optical plates on an ABI 7900HT instrument (Applied Biosystems, Carlsbad, CA, USA). Relative copy number was determined using the comparative Ct method. The Ct of the internal control (b-actin) was subtracted from that of EGFR exon 2 or intron 15 to calculate the dCt value in order to normalize the DNA. The formula 2 Â 2 -ddCt was then applied, where ddCt ¼ dCt (sample) À dCt (normal control DNA). U87 served as the normal control DNA.
Cell lines
Parental DKMG gliomas cells were obtained from the DSMZ cell line bank. DKMG cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin and 100 mg/ml kanamycin sulfate. The CAS-1 cell line was from Dr Tullio Florio (University of Genova, Italy) and the bs153 cell line from Dr Adrian Merlo (University of Basel, Switzerland). Parental U87-MG gliomas cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). U87 cells expressing EGFRvIII (U87-vIII) were a kind gift of Dr Donald O'Rourke (University of Pennsylvania, USA). U87-MG, U87-vIII, bs153 and CAS-1 cells were grown in DMEM (glucose at 4.5 g/l) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin and 100 mg/ml kanamycin sulfate. Additionally, U87-vIII cell were maintained in geneticin (G418) selection at 500 mg/ml.
For short-term cultured primary tumor experiments, freshly resected human glioblastoma tumor samples obtained from the Stanford University Tissue Bank were dissociated using collagenase and DNAse. Cells were then cultured on non-adherent plates as neurospheres using defined media containing B27 without retinoic acid (Invitrogen, Carlsbad, CA, USA), hEGF, human bFGF and heparin.
Flow cytometry
Before flow cytometry analysis or sorting, cells were washed and dissociated using TrypLE (Gibco, Carlsbad, CA, USA). Resulting suspensions of cells were resuspended in a 100 ml staining volume of FACS buffer (HBSS þ 0.1% BSA) and kept on ice during the procedure. The following antibodies were used in flow cytometry: monoclonal mouse anti-EGFRvIII antibody (G100, Zymed) and secondary anti-mouse-PE (Jackson Immuno, West Grove, PA, USA). DAPI was used to discriminate between live and dead cells. Samples were analyzed on a LSR II FACS machine (BD Biosciences, San Jose, CA, USA) or sorted on an ARIA-II (BD Biosciences) at the Stanford University FACS facility. Appropriate isotype controls were used to control for non-specific isotype background.
Western blot
Cells were lysed with cold PBS/TDS buffer (PBS with 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl fluoride, complete inhibitor cocktail; Roche Applied Science, Palo Alto, CA, USA), and the total lysate was harvested, centrifuged and used immediately or stored at À 80 1C. Equal amounts of proteins were run on 4-20% SDS-PAGE gels and transferred to nitrocellulose membranes. The signal was detected using the ECL system (Amersham Biosciences, Piscataway, NJ, USA). The following antibodies were used for immunoblotting: G100 and b-actin (Chemicon, Billerica, MA, USA).
FISH
FISH was performed on FFPE sections using a probe for the EGFR locus (7p12, Vysis LSI EGFR, SpectrumOrange, Abbott Vascular, Abbott Park, IL, USA) and CEP7 as the chromosome 7 control probe (7p11.1-q11.1 Alpha Satellite DNA, Vysis SEP7, SpectrumGreen, Abbott Vascular). Deparaffinization, hybridization, washing and counterstaining were performed according to the manufacturer's instructions. Fluorescence was visualized with an Olympus BX51 microscope equipped with an Â 100 oil immersion objective, appropriate fluorescent filters and CytoVision imaging software (Genetix Corp, San Jose, CA, USA). EGFR and CEP7 signals were quantitated in 100 cells per region. Cases were considered positive for amplification of EGFR if the EGFR/CEP7 ratio was greater than or equal to 2.0.
Long-range PCR Long-range PCR was carried out according to the methods described by Frederick et al. 28 Briefly, genomic PCR amplification were performed using the Expand Long Template PCR system (Roche Applied Science). Reactions were carried out in 50 ml total volume, containing either 20 pmol each of intron 1 sense primer mixture A or B and exon 8 antisense primer for the detection of exon 2-7 deletions or each of exon 13 sense and exon 16 antisense primer. Reaction products were electrophoresed in 0.7% agarose gels and stained with ethidium bromide. Products were excised and purified using Qiagen's gel extraction kit (Qiagen, Valencia, CA, USA) and sequencing was carried out by Elim BioPharm (Hayward, CA, USA).
RNA isolation and RT-PCR
RNA was isolated using Trizol reagent according to the manufacturer's instructions (Invitrogen) and RNA concentration and integrity was evaluated by measuring absorbance at 260 and 280 nm. To detect EGFRvIII, RT-PCR was performed using 200 ng of RNA and the One-Step RT-PCR kit (Qiagen). Primers were as follows, forward: 5 0 -GGGGAGCAGCG ATGCGACCCT-3 0 and reverse: 5 0 -ACTTGCGGACGCCGTCTTCCT-3 0 , designed to produce an 186-bp product flanking the deleted region of exons 2-7. The primers were diluted to a final concentration of 0.6 mmol/l and the remaining PCR reagents were diluted according to the manufacturer's protocol. Reverse transcription was done at 52 1C for 45 min, 60 1C for 1 min and 52 1C for 30 min, followed by enzyme inactivation and hot-start PCR at 95 1C for 15 min. Denaturation, annealing and extension were done at 93, 60 and 72 1C, for 30 s, 1 min and 45 s, respectively, for a total of 40 cycles, with a final extension period at 72 1C for 10 min. Reaction products were electrophoresed in 2% agarose gels and stained with ethidium bromide.
AZA and TSA treatment AZA was obtained (Sigma-Aldrich, St Louis, MO, USA) and dissolved into DMSO. Several aliquots of a stock solution of 100 mg/ml were prepared and stored at À 20 1C. Fresh aliquots were used for separate experiments. Cells were treated with either vehicle (DMSO) or AZA at an optimal concentration of 100 ng/ml for 48 h. Live cells were harvested for analysis of EGFRvIII expression by flow cytometry. TSA was obtained (SigmaAldrich) and dissolved into DMSO. Several aliquots of a stock solution of 100 mg/ml were prepared and stored at À 20 1C. Fresh aliquots were used for separate experiments. Cells were treated with either vehicle (DMSO) or TSA at an optimal concentration of 100 ng/ml for 48 h. Live cells were harvested for analysis of EGFRvIII expression by flow cytometry.
